Abstract
Objective the biomarkers’ performance for diagnosis and severity stratification of sepsis has not been properly evaluated anew using the SEPSIS-3 criteria introduced in 2016. We evaluated the accuracy of 21 biomarkers classically tested in sepsis research to identify infection, sepsis, and septic shock in surgical patients classified using SEPSIS-3.
Methods four groups of adult surgical patients were compared: post-surgical patients with no infection, patients with infection but no sepsis, patients with sepsis, and patients with septic shock were recruited prospectively from the surgery departments and surgical ICUs from four Spanish hospital. The area under the curve (AUC) to differentiate between groups was calculated for each biomarker.
Results A total of 187 patients were recruited (50 uninfected post-surgery controls, 50 patients with infection, 47 with sepsis and 40 with septic shock). The AUCs indicated that none of the biomarkers tested was accurate enough to differentiate those patients with infection from the uninfected controls. In contrast, procalcitonin, lipocalin 2, pentraxin 3, IL-15, TNF-α, IL-6, angiopoietin 2, TREM-1, D-dimer and C-reactive protein yielded AUCs > 0.80 to discriminate the patients with sepsis or septic shock from those with no infection. C-reactive protein and IL-6 were the most accurate markers to differentiate plain infection from sepsis (AUC = 0.82). Finally, our results revealed that sepsis and septic shock shared similar profiles of biomarkers.
Conclusion Revaluation in the “SEPSIS-3 era” identified the scenarios where biomarkers do and do not provide useful information to improve the management of surgical patients with infection or sepsis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union: Proyect (PI19/00590), Sara Borrell Research Grant (CD018/0123) (APT), PFIS Research Grant (FI20/00278) (AdF). The funding sources did not play any role in the design of the study and collection, analysis, interpretation of data or writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Committee for Ethical Research of the coordinating institution, Comite de Etica de la Investigacion con Medicamentos del Area de Salud de Valladolid Oeste, code PI142-19.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated and/or analysed during the current study are not publicly available since they are still under elaboration for publication by the authors but are available from the corresponding author on reasonable request.
List of abbreviations
- ANGPT2
- Angiopoietin 2
- AUC
- Area under the receiver operating characteristic curve
- CXCL10
- C-X-C motif chemokine ligand 10
- ICAM-1
- Intercellular adhesion molecule 1
- ICU
- Intensive care unit
- IL-6
- Interleukin 6
- IL-7
- Interleukin 7
- IL-10
- Interleukin 10
- IL-15
- Interleukin 15
- MMP7
- Matrix metalloproteinase 7
- OOP
- Optimal operating point
- PD-L1
- Programmed Death-ligand 1
- PCT
- Procalcitonin
- SOFA
- Sepsis related Organ Failure Assessment
- TNF-α
- Tumor necrosis factor α
- TREM-1
- Triggering receptor expressed on myeloid cells 1
- uPA
- Urokinase-type plasminogen activator
- VCAM-1
- Vascular cell adhesion molecule 1
